PT  - JOURNAL ARTICLE
AU  - BRÄUTIGAM, KAREN
AU  - MITZLAFF, KATHARINA
AU  - UEBEL, LISA
AU  - KÖSTER, FRANK
AU  - POLACK, STEPHAN
AU  - PERVAN, MASCHA
AU  - STEINERT, GUNNAR
AU  - RODY, ACHIM
AU  - LIEDTKE, CORNELIA
TI  - Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate
DP  - 2016 Jun 01
TA  - Anticancer Research
PG  - 2759--2766
VI  - 36
IP  - 6
4099  - http://ar.iiarjournals.org/content/36/6/2759.short
4100  - http://ar.iiarjournals.org/content/36/6/2759.full
SO  - Anticancer Res2016 Jun 01; 36
AB  - Background/Aim: Diagnosis of triple-negative breast cancer (TNBC) is associated with adverse prognosis, particularly in cases of chemotherapy resistance. The goal of this analysis was to compare TNBC vs. non-TNBC cell lines and those of distinct TNBC subtypes with regard to sensitivity to eribulin in vitro. Materials and Methods: Breast cancer cell lines were subjected to cell-viability assays, apoptosis analyses, migration and invasion experiments, and quantitative real-time polymerase chain reaction after exposure to eribulin. Results: Eribulin reduced cell viability in TNBC and non-TNBC cell lines in the sub-nanomolar range. Furthermore, exposure to eribulin induced apoptosis and decreased the rate of migration and invasion. Genes known to induce malignant transformation were differentially expressed after eribulin treatment. Conclusion: Eribulin had a strong antiproliferative effect on breast cancer cell lines, although we did not observe a significant difference between TNBC and non-TNBC cell lines with regard to sensitivity to eribulin.